Alzheimer’s Disease (AD) is a devastating disease of brain aging that causes progressive, severe memory loss. There is no effective “drug” to prevent or treat AD and we believe that it is unlikely that any will be developed in the near future. Therefore, other therapeutic interventions are desperately needed.

To meet this need, NeuroEM Therapeutics has developed a first-in-class, self-contained head device (the MemorEM 1000) to prevent and treat AD with electromagnetic waves – a therapy that we have pioneered and tested successfully in AD animal studies with no adverse events seen in the animals. Our novel, proprietary technology appears to directly affect the AD process to prevent and reverse memory loss. The MemorEM 1000 head device has been successfully used in NeuroEM’s recently completed Phase I clinical trial that evaluated the safety and efficacy of Transcranial Electromagnetic Treatment (TEMT) in Alzheimer’s patients.

TEMT is an investigational device currently under development and not commercially available.
  • In the news
    • 03/29/19
      NeuroEM Therapeutics Announces Addition of Two New Members to its Board of Directors
    • 01/08/19
      NeuroEM Therapeutics Announces Completion of Clinical Trial Testing Its Novel Head Device Against Alzheimer’s Disease
    • 07/28/17
      Alzheimer’s Clinical Trial Begins with Pioneering Medical Device
    • 12/08/16
      National Institutes of Health Bestows Grant to NeuroEM Therapeutics and Arizona State University for Collaborative Research in Alzheimer’s Disease
    • 11/23/16
      NeuroEM Therapeutic’s CEO provides keynote address at Australian conference on biologic effects of electromagnetic exposure
    • 05/02/16
      Angel Investment Forum Provides “Series Seed” Funding to NeuroEM Therapeutics to Support Development of Medical Device against Alzheimer’s Disease
    • 02/19/16
      NeuroEM Therapeutics Secures over Half Million Dollars in Funding to Perform Clinical Trial Testing It’s Medical Device for Alzheimer’s Disease
    • 01/04/16
      NeuroEM Therapeutics Receives Clinical Trial Approval to Test its Novel Head Device in Alzheimer’s Patients

“An innovative company hits a target that no other company can hit,
but a disruptive company hits a target no other company can see”